Skip to content
- BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
- Scott R, Rimel BJ.
- OncLive. 2022 Nov 4.
- Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
- Matta BP, Gomes R, Mattos D, Olicio R, Nascimento CM, Ferreira GM, Brant AC, Boroni M, Furtado C, Lima V, Moreira MÂM, Dos Santos ACE.
- Sci Rep. 2022 Nov 3;12(1):18629. doi: 10.1038/s41598-022-23012-3.
- Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
- Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA.
- JCO Precis Oncol. 2022 Nov;6:e2200309. doi: 10.1200/PO.22.00309.